Safety of hematopoietic stem cell donation in glucose 6 phosphate dehydrogenase-deficient donors

Bone Marrow Transplant. 2013 Jan;48(1):36-9. doi: 10.1038/bmt.2012.112. Epub 2012 Jun 25.

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common RBC enzymatic disorder in humans capable of producing hemolytic events. Recently, concern has been raised about using G6PD-deficienct subjects as hemopoietic stem cell (HSC) donors. In a 10-year period, 101 consecutive HSC donors were submitted to donation procedures for transplantation inside their families in our Center. All donors were tested for G6PD and 19 (19%) turned out to be G6PD-deficient. The donors' safety and the effectiveness of these transplant outcomes were compared with those of the remaining 82 donors. No difference could be observed in any safety parameter between the two groups. No difference was recorded in donors' complications rates, in HSC production, in quantity of growth factor required, in Hb early drop or in Hb recovery. No difference was found in transplant outcome. From this retrospective analysis, we conclude that a G6PD-deficient but otherwise healthy volunteer can be selected as a HSC donor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Donors
  • Bone Marrow Transplantation / adverse effects
  • Cohort Studies
  • Cytapheresis*
  • Directed Tissue Donation*
  • Family Health
  • Female
  • Filgrastim
  • Follow-Up Studies
  • Glucosephosphate Dehydrogenase Deficiency / complications
  • Glucosephosphate Dehydrogenase Deficiency / etiology
  • Glucosephosphate Dehydrogenase Deficiency / metabolism
  • Glucosephosphate Dehydrogenase Deficiency / pathology*
  • Granulocyte Colony-Stimulating Factor / adverse effects
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Hematologic Agents / adverse effects
  • Hematologic Agents / metabolism
  • Hematologic Agents / pharmacology
  • Hematopoiesis / drug effects
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / metabolism
  • Hematopoietic Stem Cells / pathology*
  • Humans
  • Italy
  • Male
  • Mediterranean Islands
  • Middle Aged
  • Myelodysplastic Syndromes / blood
  • Myelodysplastic Syndromes / complications
  • Myelodysplastic Syndromes / metabolism
  • Myelodysplastic Syndromes / therapy*
  • Peripheral Blood Stem Cell Transplantation / adverse effects
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / pharmacology
  • Retrospective Studies
  • Tissue Donors

Substances

  • Hematologic Agents
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Filgrastim